Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Ethanol-lock treatment may help prevent central venous catheter infections in patients with high-risk neuroblastoma.

PURPOSE: This phase I trial is studying the side effects of ethanol-lock treatment in preventing central venous catheter infections in patients with high-risk neuroblastoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Ethanol

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of neuroblastoma by histopathology OR bone marrow metastases and high urine catecholamine levels

• High-risk disease

• Currently enrolled on clinical trial MSKCC-03077

• Expected duration of therapy ≥ 6 months

• Surgically-implanted central venous catheter with documented patency

• Must be able to establish patency of central venous catheter lumen

• No history of culture-positive central venous catheter infection in catheter to be treated

PATIENT CHARACTERISTICS:

• Bilirubin < 1.5 times upper limit of normal (ULN)

• AST and ALT < 2.5 times ULN

• Alkaline phosphatase < 2.5 times ULN

• No history of hypersensitivity to ethanol

• No history or documented active seizure disorder

• No documented acute liver failure

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No concurrent total parenteral nutrition or other infusion requiring use of the central line at night

• No concurrent levetiracetam or other anticonvulsants